During Friday's "Lightning Round" segment of Mad Money, one caller quizzed Jim Cramer about NantKwest (NK) . "I'm going to say yes to this speculative company. I'm fine with it," said Cramer about this a clinical-stage immunotherapy company.
More from Investing
When you put them together, trading success is nearly inevitable.
You can't call this market overbought when so much of it isn't participating.
SKLZ shows explosion moves to the upside when it emerges from the oversold area.